Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Nona Biosciences Partners with Medical University of Vienna on Infectious Disease Antibody Research Using Proprietary H2L2 Harbour Mice Platform

Fineline Cube Jul 24, 2026
Company Deals

Pakistan-China Pharma Pact: $440M in Agreements Positions Pakistan as Regional Medicines Hub

Fineline Cube Jul 24, 2026
Company Deals

Summit Therapeutics and Arcus Biosciences Launch Global Trial of Ivonescimab-Casdatifan Combination for Renal Cell Carcinoma

Fineline Cube Jul 23, 2026
Company Deals

Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II

Fineline Cube Jul 22, 2026
Company Deals

TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal

Fineline Cube Jul 22, 2026
Policy / Regulatory

Trump Announces Phased Tariff Policy on Generic Drug Imports to Incentivize U.S. Manufacturing Reshoring

Fineline Cube Jul 23, 2026
Company Drug

Walvax Biotechnology’s Bivalent HPV Vaccine WALRINVAX Gains Tanzanian Approval Following WHO Prequalification

Fineline Cube Jul 24, 2026
Company Drug

Kanghong Pharmaceutical Secures NMPA Approval for KHN921 Gene Therapy in MYBPC3-Related Hypertrophic Cardiomyopathy Following U.S. FDA Clearance

Fineline Cube Jul 24, 2026
Company Drug

Simcere Secures Approval for Local Manufacturing of Cosela, Boosting Patient Access

Fineline Cube Dec 28, 2023

China-based Simcere Pharmaceutical Group (HKG: 2096) has received supplementary filing approval for its drug Cosela...

Company

Chengda Pharmaceuticals Halts Shanghai Research Project Amid Market Challenges

Fineline Cube Dec 28, 2023

Chengda Pharmaceuticals Co. Ltd. (SHE: 301201), based in China, has announced the termination of its...

Company Deals

TYK Medicines Secures Nearly RMB 200 Million in Series D Financing Led by Sichuan Huiyu Pharmaceutical

Fineline Cube Dec 28, 2023

Shanghai-based TYK Medicines (HKG: 2410) has successfully completed a Series D financing round, raising nearly...

Company Medical Device

NMPA Approves Pulnovo Medical’s Novel Catheter for Treating Pulmonary Arterial Hypertension

Fineline Cube Dec 28, 2023

The National Medical Products Administration (NMPA) has granted marketing approval for Pulnovo Medical’s disposable circular...

Company Deals

Innovent Biologics Partners with Xuanzhu Biopharma for Clinical Trial of Sintilimab and KM-501 in Advanced Tumors

Fineline Cube Dec 28, 2023

Innovent Biologics, Inc. (HKG: 1801), based in China, has entered into a clinical trial collaboration...

Company Drug

Sanofi Gains NMPA Approval for Innovative Rosuvastatin and Ezetimibe Combination Therapy

Fineline Cube Dec 28, 2023

Sanofi (NASDAQ: SNY), the French pharmaceutical giant, has announced that it has received market approval...

Company Deals

Janssen Acquires Rights to Gene Therapy Botaretigene Sparoparvovec from MeiraGTx for XLRP Treatment

Fineline Cube Dec 28, 2023

Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson (J&J, NYSE: JNJ), announced last week its...

Company Drug

AstraZeneca Secures FDA Approval for Self-Administered hATTR-PN Therapy Wainua

Fineline Cube Dec 28, 2023

AstraZeneca (AZ, NASDAQ: AZN), headquartered in the UK, announced last week that the U.S. Food...

Company Deals

Elpiscience Partners with Astellas for Bi-Specific Macrophage Engager Research

Fineline Cube Dec 28, 2023

China-based Elpiscience Biopharmaceuticals has announced a research collaboration and licensing agreement with Japan’s Astellas Pharma...

Company Deals

Panlin Capital Raises Second Fund Focused on Biopharmaceutical Innovation

Fineline Cube Dec 27, 2023

Panlin Capital has announced the successful closing of its second venture capital fund, the Hangzhou...

Company Deals

XRGenesis Raises $14 Million in Series A to Advance Ophthalmic Surgical Technology

Fineline Cube Dec 27, 2023

XRGenesis, a developer of high-end ophthalmic surgical equipment based in Hangzhou, has reportedly raised nearly...

Company Drug

Taiwan FDA Reviews Nefecon New Drug Application from Everest Medicines

Fineline Cube Dec 27, 2023

China-based Everest Medicines (HKG: 1952) has announced that the New Drug Application (NDA) for Nefecon...

Company Deals

J&J’s Janssen Secures Exclusive Global Rights to Develop LCB84 ADC from LegoChem Biosciences

Fineline Cube Dec 27, 2023

Johnson & Johnson’s (J&J; NYSE: JNJ) pharmaceutical subsidiary, Janssen, has entered into an exclusive global...

Company Deals

BMS Expands Oncology Portfolio with $4.1 Billion RayzeBio Acquisition

Fineline Cube Dec 27, 2023

Bristol Myers Squibb (BMS; NYSE: BMY) has announced the acquisition of RayzeBio (NASDAQ: RYZB), a...

Company Drug

Amgen’s Lumakras Faces Full Approval Delay as FDA Requests New Study

Fineline Cube Dec 27, 2023

The US Food and Drug Administration (FDA) has declined to grant full approval for Amgen’s...

Policy / Regulatory

China’s NMPA Proposes Enhanced IT and Visualization Requirements for Blood Product GMP

Fineline Cube Dec 27, 2023

The National Medical Products Administration (NMPA) of China is currently soliciting public feedback on the...

Company Medical Device

Fresenius Medical Care Expands Dialysis Solutions in China with 6008 CARESystem Launch

Fineline Cube Dec 27, 2023

Fresenius Medical Care AG has announced the official launch of its 6008 CARESystem hemodialysis filtration...

Policy / Regulatory

China Charts Course for Advanced Disease Prevention and Control System by 2030

Fineline Cube Dec 27, 2023

China’s State Council has issued the “Guiding Opinions on Promoting the High Quality Development of...

Company Deals

Innovent Biologics Partners with Sanegene Bio USA to Develop Hypertension Drug

Fineline Cube Dec 27, 2023

China-based Innovent Biologics (HKG: 1801) has entered into a partnership with Sanegene Bio USA Inc....

Company Drug

Guangdong Zhongsheng Pharmaceutical’s ZSP1273 for Influenza A Accepted for Review by NMPA

Fineline Cube Dec 27, 2023

Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a Chinese pharmaceutical company, has announced that China’s...

Posts pagination

1 … 457 458 459 … 699

Recent updates

  • Walvax Biotechnology’s Bivalent HPV Vaccine WALRINVAX Gains Tanzanian Approval Following WHO Prequalification
  • Kanghong Pharmaceutical Secures NMPA Approval for KHN921 Gene Therapy in MYBPC3-Related Hypertrophic Cardiomyopathy Following U.S. FDA Clearance
  • Changchun High-Tech Subsidiary GeneScience Files SLE Clinical Application for Novel Dual-Target BAFF/APRIL Inhibitor GenSci136
  • Lilly’s Retatrutide Delivers Up to 22.6% Weight Loss in Phase 3 Trials, Establishing Triple Agonist Leadership in Obesity Market
  • Aidea Pharma Secures NMPA Approval for Darunavir, Challenging J&J’s Prezista in China’s HIV Treatment Market
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Walvax Biotechnology’s Bivalent HPV Vaccine WALRINVAX Gains Tanzanian Approval Following WHO Prequalification

Company Drug

Kanghong Pharmaceutical Secures NMPA Approval for KHN921 Gene Therapy in MYBPC3-Related Hypertrophic Cardiomyopathy Following U.S. FDA Clearance

Company Drug

Changchun High-Tech Subsidiary GeneScience Files SLE Clinical Application for Novel Dual-Target BAFF/APRIL Inhibitor GenSci136

Company Drug

Lilly’s Retatrutide Delivers Up to 22.6% Weight Loss in Phase 3 Trials, Establishing Triple Agonist Leadership in Obesity Market

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.